SPECT/CT and tumour imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue SUPPL. 1, 2014, Pages

  Abikhzer, Gad ^a   Keidar, Zohar ^a,b  

^a Department of Nuclear Medicine Rambam Health Care Campus ^*  (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Hybrid imaging; SPECT CT; Tumour

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; BISPHOSPHONIC ACID DERIVATIVE; CAPROMAB PENDETIDE IN 111; IODINE 131; METHYLENE DISPHOSPHONATE TC 99M; PENTETREOTIDE IN 111; TECHNETIUM 99M; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LYMPHOSCINTIGRAPHY; NEOPLASM; ONCOLOGY; PARATHYROID ADENOMA; PROSTATE CANCER; REVIEW; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; MULTIMODAL IMAGING; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84905583221     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2534-4     Document Type: Review

References (111)

1. Beyer T, Freudenberg LS, Townsend DW, Czernin J. The future of hybrid imaging - part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging. 2011;2:161-9.
2. Reinartz P, Schaffeldt J, Sabri O, Zimny M, Nowak B, Ostwald E, et al. Benign versus malignant osseous lesions in the lumbar vertebrae: differentiation by means of bone SPET. Eur J Nucl Med. 2000;27:721-6.
3. Abikhzer G, Kennedy J, Israel O. 18F NaF PET/CT and conventional bone scanning in routine clinical practice: comparative analysis of tracers, clinical acquisition protocols, and performance indices. PET Clin. 2012;7:315-28.
4. Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37:706-13.
5. Romer W, Nomayr A, Uder M, Bautz W, Kuwert T. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med. 2006;47:1102-6.
6. Sharma P, Singh H, Kumar R, Bal C, Thulkar S, Seenu V, et al. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun. 2012;33:139-47.
7. Utsunomiya D, Shiraishi S, Imuta M, Tomiguchi S, Kawanaka K, Morishita S, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology. 2006;238:264-71.
8. Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun. 2010;31:659-65.
9. Nakamoto Y, Cohade C, Tatsumi M, Hammoud D, Wahl RL. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology. 2005;237:627-34.
10. Buscombe J, Paganelli G, Burak ZE, Waddington W, Maublant J, Prats E, et al. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging. 2007;34:2154-9.
11. Chakera AH, Hesse B, Burak Z, Ballinger JR, Britten A, Caraco C, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713-42.
12. Alazraki N, Glass EC, Castronovo F, Olmos RA, Podoloff D. Procedure guideline for lymphoscintigraphy and the use of intraoperative gamma probe for sentinel lymph node localization in melanoma of intermediate thickness 1.0. J Nucl Med. 2002;43:1414-8.
13. Schneebaum S, Even-Sapir E, Cohen M, Shacham-Lehrman H, Gat A, Brazovsky E, et al. Clinical applications of gamma-detection probes - radioguided surgery. Eur J Nucl Med. 1999;26:S26-35.
14. Gennari R, Bartolomei M, Testori A, Zurrida S, Stoldt HS, Audisio RA, et al. Sentinel node localization in primary melanoma: preoperative dynamic lymphoscintigraphy, intraoperative gamma probe, and vital dye guidance. Surgery. 2000;127:19-25.
15. Sumner 3rd WE, Ross MI, Mansfield PF, Lee JE, Prieto VG, Schacherer CW, et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002;95:354-60.
16. Alkureishi LW, Burak Z, Alvarez JA, Ballinger J, Bilde A, Britten AJ, et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1915-36.
17. Khafif A, Schneebaum S, Fliss DM, Lerman H, Metser U, Ben-Yosef R, et al. Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma. Head Neck. 2006;28:874-9.
18. Wagner A, Schicho K, Glaser C, Zettinig G, Yerit K, Lang S, et al. SPECT-CT for topographic mapping of sentinel lymph nodes prior to gamma probe-guided biopsy in head and neck squamous cell carcinoma. J Craniomaxillofac Surg. 2004;32:343-9.
19. Keski-Santti H, Matzke S, Kauppinen T, Tornwall J, Atula T. Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2006;263:1008-12.
20. Nomori H, Ikeda K, Mori T, Kobayashi H, Iwatani K, Kawanaka K, et al. Sentinel node navigation segmentectomy for clinical stage IA nonsmall cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:780-5.
21. Tsai JA, Celebioglu F, Lindblad M, Lorinc E, Nilsson M, Olsson A, et al. Hybrid SPECT/CT imaging of sentinel nodes in esophageal cancer: first results. Acta Radiol. 2013;54:369-73.
22. Lerman H, Metser U, Lievshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33:329-37.
23. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48:201-6.
24. Van Der Ploeg IM, Valdes Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48:1756-60.
25. Kraft O, Havel M. Detection of sentinel lymph nodes in gynecologic tumours by planar scintigraphy and SPECT/CT. Mol Imaging Radionucl Ther. 2012;21:47-55.
26. Sherif A, Garske U, De La Torre M, Thorn M. Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol. 2006;50:83-91.
27. Vermeeren L, Valdes Olmos RA, Meinhardt W, Bex A, Van Der Poel HG, Vogel WV, et al. Value of SPECT/CT for detection and anatomic localization of sentinel lymph nodes before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. J Nucl Med. 2009;50:865-70.
28. Ganswindt U, Schilling D, Muller AC, Bares R, Bartenstein P, Belka C. Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys. 2011;79:1364-72.
29. Leijte JA, Van Der Ploeg IM, Valdes Olmos RA, Nieweg OE, Horenblas S. Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. J Nucl Med. 2009;50:364-7.
30. Leijte JA, Valdes Olmos RA, Nieweg OE, Horenblas S. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: implications for the extent of inguinal lymph node dissection. Eur Urol. 2008;54:885-90.
31. Van Den Berg NS, Valdes-Olmos RA, Van Der Poel HG, Van Leeuwen FW. Sentinel lymph node biopsy for prostate cancer: a hybrid approach. J Nucl Med. 2013;54:493-6.
32. Cheville AL, Brinkmann DH, Ward SB, Durski J, Laack NN, Yan E, et al. The addition of SPECT/CT lymphoscintigraphy to breast cancer radiation planning spares lymph nodes critical for arm drainage. Int J Radiat Oncol Biol Phys. 2013;85:971-7.
33. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18.
34. Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas. J Nucl Med. 1999;40:539-53.
35. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542-9.
36. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CTand MR imaging. QJM. 1998;91:295-301.
37. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-10.
38. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-31.
39. Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, et al. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol. 2011;39:317-24.
40. Steffen IG, Mehl S, Heuck F, Elgeti F, Furth C, Amthauer H, et al. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Clin Nucl Med. 2009;34:869-73.
41. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441-8.
42. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59:565-73.
43. Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med. 2008;113:1056-67.
44. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2008;52:323-33.
45. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol. 2010;17:291-7.
46. Apostolova I, Riethdorf S, Buchert R, Derlin T, Brenner W, Mester J, et al. SPECT/CT stabilizes the interpretation of somatostatin receptor scintigraphy findings: a retrospective analysis of inter-rater agreement. Ann Nucl Med. 2010;24:477-83.
47. Hillel PG, Van Beek EJ, Taylor C, Lorenz E, Bax ND, Prakash V, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol. 2006;61:579-87.
48. Pfannenberg AC, Eschmann SM, Horger M, Lamberts R, Vonthein R, Claussen CD, et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2003;30:835-43.
49. Beierwaltes WH. Endocrine imaging: parathyroid, adrenal cortex and medulla, and other endocrine tumors. Part II. J Nucl Med. 1991;32:1627-39.
50. Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med. 1995;25:235-50.
51. Meyer-Rochow GY, Schembri GP, Benn DE, Sywak MS, Delbridge LW, Robinson BG, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol. 2010;17:392-400.
52. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998;39:679-88.
53. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466-77.
54. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CTover planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med. 2011;36:1-7.
55. Ozer S, Dobrozemsky G, Kienast O, Beheshti M, Becherer A, Niederle B, et al. Value of combined XCT/SPECT technology for avoiding false positive planar (123) I-MIBG scintigraphy. Nuklearmedizin. 2004;43:164-70.
56. Sharma P, Dhull VS, Jeph S, Reddy RM, Singh H, Naswa N, et al. Can hybrid SPECT-CT overcome the limitations associated with poor imaging properties of 131I-MIBG?: comparison with planar scintigraphy and SPECT in pheochromocytoma. Clin Nucl Med. 2013;38:e346-53.
57. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol. 2008;190:1085-90.
58. Scott AM, Macapinlac H, Zhang J, Daghighian F, Montemayor N, Kalaigian H, et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med. 1995;36:100-3.
59. Yamamoto Y, Nishiyama Y, Monden T, Matsumura Y, Satoh K, Ohkawa M. Clinical usefulness of fusion of 131I SPECT and CT images in patients with differentiated thyroid carcinoma. J Nucl Med. 2003;44:1905-10.
60. Shapiro B, Rufini V, Jarwan A, Geatti O, Kearfott KJ, Fig LM, et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med. 2000;30:115-32.
61. Mustafa M, Kuwert T, Weber K, Knesewitsch P, Negele T, Haug A, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur J Nucl Med Mol Imaging. 2010;37:1462-6.
62. Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435-42.
63. Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch HJ, Gomez-Segovia I, Matschnig S, et al. Posttherapeutic (131) I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36:886-93.
64. Glazer DI, Brown RK, Wong KK, Savas H, Gross MD, Avram AM. SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiographics. 2013;33:397-418.
65. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, et al. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952-7.
66. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18-23.
67. Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184-90.
68. Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131) I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94:2075-84.
69. Barwick T, Murray I, Megadmi H, Drake WM, Plowman PN, Akker SA, et al. Single photon emission computed tomography (SPECT)/computed tomography using iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162:1131-9.
70. Blum M, Tiu S, Chu M, Goel S, Friedman K. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients. Thyroid. 2011;21:1235-47.
71. Schmidt D, Linke R, Uder M, Kuwert T. Five months' follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by (131) I-SPECT/CT at the first radioablation. Eur J Nucl Med Mol Imaging. 2010;37:699-705.
72. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, et al. The effect of posttherapy 131I SPECT/CTon risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51:1361-7.
73. Mariani G, Gulec SA, Rubello D, Boni G, Puccini M, Pelizzo MR, et al. Preoperative localization and radioguided parathyroid surgery. J Nucl Med. 2003;44:1443-58.
74. Slater A, Gleeson FV. Increased sensitivity and confidence of SPECTover planar imaging in dual-phase sestamibi for parathyroid adenoma detection. Clin Nucl Med. 2005;30:1-3.
75. Casara D, Rubello D, Pelizzo MR, Shapiro B. Clinical role of 99mTcO4/MIBI scan, ultrasound and intra-operative gamma probe in the performance of unilateral and minimally invasive surgery in primary hyperparathyroidism. Eur J Nucl Med. 2001;28:1351-9.
76. Casara D, Rubello D, Piotto A, Pelizzo MR. 99mTc-MIBI radioguided minimally invasive parathyroid surgery planned on the basis of a preoperative combined 99mTc-pertechnetate/99mTc-MIBI and ultrasound imaging protocol. Eur J Nucl Med. 2000;27:1300-4.
77. 99m-sestamibi parathyroid scintigraphy. J Nucl Med. 1996;37:1773-8.
78. 99m sestamibi SPECT. Radiology. 1996;201:85-91.
79. Sfakianakis GN, Irvin 3rd GL, Foss J, Mallin W, Georgiou M, Deriso GT, et al. Efficient parathyroidectomy guided by SPECT-MIBI and hormonal measurements. J Nucl Med. 1996;37:798-804.
80. 99m sestamibi parathyroid scintigraphy. Clin Nucl Med. 2009;34:651-5.
81. Lorberboym M, Minski I, Macadziob S, Nikolov G, Schachter P. Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. J Nucl Med. 2003;44:904-8.
82. Buck AK, Nekolla S, Ziegler S, Beer A, Krause BJ, Herrmann K, et al. SPECT/CT. J Nucl Med. 2008;49:1305-19.
83. Bural GG, Muthukrishnan A, Oborski MJ, Mountz JM. Improved benefit of SPECT/CT compared to SPECT alone for the accurate localization of endocrine and neuroendocrine tumors. Mol Imaging Radionucl Ther. 2012;21:91-6.
84. Kim YI, Jung YH, Hwang KT, Lee HY. Efficacy of 99mTcsestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with 99mTc-sestamibi scintigraphy, SPECT, US and CT. Ann Nucl Med. 2012;26:804-10.
85. Papathanassiou D, Flament JB, Pochart JM, Patey M, Marty H, Liehn JC, et al. SPECT/CT in localization of parathyroid adenoma or hyperplasia in patients with previous neck surgery. Clin Nucl Med. 2008;33:394-7.
86. 99m technetium-sestamibi SPECT/CT compared to conventional SPECT in patients with primary hyperparathyroidism and concomitant nodular goiter. Thyroid. 2010;20:1121-7.
87. Shafiei B, Hoseinzadeh S, Fotouhi F, Malek H, Azizi F, Jahed A, et al. Preoperative 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism and concomitant nodular goiter: comparison of SPECT-CT, SPECT, and planar imaging. Nucl Med Commun. 2012;33:1070-6.
88. Zhen L, Li H, Liu X, Ge BH, Yan J, Yang J. The application of SPECT/CT for preoperative planning in patients with secondary hyperparathyroidism. Nucl Med Commun. 2013;34:439-44.
89. Gayed IW, Kim EE, Broussard WF, Evans D, Lee J, Broemeling LD, et al. The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J Nucl Med. 2005;46:248-52.
90. 99m SPECT-CT hybrid images in predicting the precise intraoperative anatomical location of parathyroid adenomas. Head Neck. 2008;30:509-17.
91. 99m-MIBI SPECT/CT in primary hyperparathyroidism. World J Surg. 2006;30:76-83.
92. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, et al. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase 99mTc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007;48:1084-9.
93. Greenspan BS, Dillehay G, Intenzo C, Lavely WC, O'Doherty M, Palestro CJ, et al. SNM practice guideline for parathyroid scintigraphy 4.0. J Nucl Med Technol. 2012;40:111-8.
94. Hunter GJ, Schellingerhout D, Vu TH, Perrier ND, Hamberg LM. Accuracy of four-dimensional CT for the localization of abnormal parathyroid glands in patients with primary hyperparathyroidism. Radiology. 2012;264:789-95.
95. Haseman MK, Rosenthal SA, Polascik TJ. Capromab pendetide imaging of prostate cancer. Cancer Biother Radiopharm. 2000;15:131-40.
96. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology. 2000;56:988-93.
97. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998;83:739-47.
98. Kelty NL, Holder LE, Khan SH. Dual-isotope protocol for indium-111 capromab pendetide monoclonal antibody imaging. J Nucl Med Technol. 1998;26:174-7.
99. Quintana JC, Blend MJ. The dual-isotope ProstaScint imaging procedure: clinical experience and staging results in 145 patients. Clin Nucl Med. 2000;25:33-40.
100. Wong TZ, Turkington TG, Polascik TJ, Coleman RE. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol. 2005;184:676-80.
101. Ellis RJ, Zhou EH, Fu P, Kaminsky DA, Sodee DB, Faulhaber PF, et al. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set coregistration independently predicts biochemical failure. J Urol. 2008;179:1768-73. discussion 73-4.
102. Kimura M, Tsivian M, Mouraviev V, Mayes JM, Price MM, Bannister MC, et al. Utilization of (111) In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int J Urol. 2009;16:971-5.
103. Ellis RJ, Zhou H, Kaminsky DA, Fu P, Kim EY, Sodee DB, et al. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion. Brachytherapy. 2007;6:149-56.
104. Ellis RJ, Zhou H, Kim EY, Fu P, Kaminsky DA, Sodee B, et al. Biochemical disease-free survival rates following definitive lowdose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy. 2007;6:16-25.
105. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006;36:212-27.
106. Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50:1631-7.
107. Mueller B, O'Connor MK, Blevis I, Rhodes DJ, Smith R, Collins DA, et al. Evaluation of a small cadmium zinc telluride detector for scintimammography. J Nucl Med. 2003;44:602-9.
108. Schillaci O, Danieli R, Filippi L, Romano P, Cossu E, Manni C, et al. Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res. 2007;27:557-62.
109. Palumbo B, Sivolella S, Palumbo I, Liberati AM, Palumbo R. 67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:1011-7.
110. Filippi L, Santoni R, Nicoli P, Danieli R, Schillaci O. Intracranial tumors after radiation therapy: role of 99mTc-tetrofosmin SPECT/CT with a hybrid camera. Cancer Biother Radiopharm. 2009;24:229-35.
111. 99m] tetrofosmin. Cancer Biother Radiopharm. 2006;21:41-8.